COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that it will submit an amended test protocol to the FDA and almost simultaneously in Canada to cover dose escalation studies of Oxycyte® in Traumatic Brain Injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. The company intends to file the amended protocol in global format, which allows for submission in the U.S. and other countries, within approximately 50 days.
